Positive results from Visudyne(R) combination therapy study reported at Annual Macula Society ...(fer materially from those currently anti...),Health

Date:3/28/2008

fer materially from those currently anticipated due to a number of factors, which include, but are not limited to: the completion and results of studies on combination therapy, the level of physician acceptance of Visudyne in combination with other agents and the cost associated with such treatments is uncertain, and other factors as described in detail in QLT's Annual Information Form and Annual Report on Form 10-K, quarterly reports on Form 10-Q and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward-looking statements are based on the current expectations of QLT and QLT does not assume any obligation to update such information to reflect later events or developments except as required by law.

CONTACT: QLT Inc.: Vancouver, Canada, Therese Hayes, Telephone: (604) 707-7000, or 1-800-663-5486, Fax: (604)-707-7001

'/>"/>

SOURCE QLT Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine news :

1. Cystic Fibrosis Foundation announces positive early results for phase 2 clinical trial of VX-770
2. MRIs high false positive rate has little impact on womens choice of preventive mastectomy
3. AcroMetrix Announces Launch of First Liquid MRSA Positive Control
4. Make Your Mammogram a Positive Experience: Author Offers Guidelines and Tips to Change Womens Negative Attitudes Toward Mammograms
5. QLT announces positive FDA action on Aczone(TM)
6. Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
7. Echo Therapeutics Announces Positive Results from Symphony(TM) Transdermal Continuous Glucose Monitoring System Study at Tufts Medical Center
8. Ibuprofen destroys aspirins positive effect on stroke risk
9. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
10. Positive results from phase 1 clinical trials of cuprindro
11. Single reader with CAD more efficient, yields fewer false positives, and possibly more sensitive